Upload
Featured Recent Articles Topics Login Upload

Search Results for 'Prasugrel'

Prasugrel published presentations and documents on DocSlides.

Prasugrel vs ticagrelor in acute coronary syndromes
Prasugrel vs ticagrelor in acute coronary syndromes
by tawny-fly
Giuseppe . Biondi-Zoccai. , MD. Sapienza Universi...
Pharmacodynamic Effects of
Pharmacodynamic Effects of
by luanne-stotts
Cangrelor. . on . Platelet P2Y. 12. Receptor . ...
ACCOAST: no difference
ACCOAST: no difference
by debby-jeon
ACCOAST: no difference in efficacy endpoin...
Antiplatelet Agents Mohammad Sistanizad
Antiplatelet Agents Mohammad Sistanizad
by blindnessinfluenced
Associate Professor of Clinical Pharmacy,. SBMU. C...
Application
Application
by natalia-silvester
0 Phase 1 Phase 2 Phase 3 Therapeutic area Cardiov...
Canadian Diabetes Association Clinical Practice Guidelines
Canadian Diabetes Association Clinical Practice Guidelines
by test
Acute Coronary Syndromes and Diabetes. Chapter 26...
When should we start a
When should we start a
by myesha-ticknor
P2Y. 12. inhibitor . in patients with an acute c...
ISAR-REACT 5, comment
ISAR-REACT 5, comment
by trish-goza
ISAR-REACT 5, comment G. Montalescot Institute o...
De-escalation versus escalation of antiplatelet therapy in elderly ACS patients: insight from the ANTARCTIC trial.
De-escalation versus escalation of antiplatelet therapy in elderly ACS patients: insight from the ANTARCTIC trial.
by debby-jeon
De-escalation versus escalation of antiplatelet t...
ACCP Cardiology PRN Journal Club
ACCP Cardiology PRN Journal Club
by marina-yarberry
ACCP Cardiology PRN Journal Club 27 September 20...
On behalf of the TRILOGY ACS Investigators
On behalf of the TRILOGY ACS Investigators
by lam
Prasugrel versus clopidogrel for patients with . U...
Sumith Aleti , MD, MPH, FACC
Sumith Aleti , MD, MPH, FACC
by dorothy
OHHI Cardiology Group. Antiplatelet and Anticoagul...
Switching from dual antiplatelet therapy with aspirin plus a P2Y
Switching from dual antiplatelet therapy with aspirin plus a P2Y
by brown
12. inhibitor to dual pathway inhibition with asp...